Aquestive Therapeutics, Inc. AQST Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 58.3%-10.6pp | 69%+10.1pp | 58.8%-0.5pp | 59.3%— | |
| Operating margin | -159.5%-106pp | -53.5%-23.6pp | -29.9%+58.4pp | -88.2%-20.0pp | |
| Net margin | -188.1%-111pp | -76.7%-61.1pp | -15.6%+98.6pp | -114.1%+24.7pp | |
| Efficiency | |||||
| Asset turnover | 0.3×-0.4× | 0.7×-0.2× | 0.9×+0.1× | 0.8×0.0× | |
| Liquidity | |||||
| Current ratio | 3.1×-1.5× | 4.7×+2.4× | 2.2×+1.2× | 1×-1.1× | |
| Per Share | |||||
| Book value per share | -$0.31+54.6% | -$0.69+60.1% | -$1.74+28.5% | -$2.43-12.8% | |
| Valuation | |||||
| Market capitalization | $560.13M+73.5% | $324.59M+141% | $134.87M+176% | $48.85M-68.7% | |
| Price / sales | 11.1×+5.2× | 5.6×+3.0× | 2.7×+1.6× | 1×-2.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aquestive Therapeutics, Inc.'s profit margins?
- Aquestive Therapeutics, Inc. (AQST) runs a 63.5% gross margin and a -111.2% operating margin, with a -137.1% net margin.
- Where do Aquestive Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Aquestive Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
